Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET
- 146 Downloads
The aim of this study was to assess the influence of age on the functional activity of the multidrug efflux transporter P-glycoprotein (P-gp) at the human blood-brain barrier.
Seven young (mean age: 27 ± 4 years) and six elderly (mean age: 69 ± 9 years) healthy volunteers underwent dynamic (R)-[11C]verapamil (VPM) positron emission tomography (PET) scans and arterial blood sampling. Parametric distribution volume (DV) images were generated using Logan linearisation, and age groups were compared with statistical parametric mapping (SPM). Brain regions that SPM analysis had shown to be most affected by age were analysed by a region of interest (ROI)-based approach using a maximum probability brain atlas, before and after partial volume correction (PVC).
SPM analysis revealed significant clusters of DV increases in cerebellum, temporal and frontal lobe of elderly compared to younger subjects. In the ROI-based analysis, elderly subjects showed significant DV increases in amygdala (+30%), insula (+26%) and cerebellum (+25%) before PVC, and in insula (+33%) after PVC.
Increased VPM DV values in the brains of elderly subjects suggest a decrease in cerebral P-gp function with increasing age.
KeywordsP-glycoprotein Blood-brain barrier Age (R)-[11C]verapamil Positron emission tomography
The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 201380 and from the Austrian Science Fund (FWF) project ‘Transmembrane Transporters in Health and Disease’ (SFB F35). This study would not have been possible without the excellent support of Rainer Bartosch (Department of Nuclear Medicine), and Edith Lackner and Johann Stanek (Department of Clinical Pharmacology). The authors wish to thank Gert Luurtsema, Mark Lubberink and Adriaan Lammertsma from the VU University Medical Center (Amsterdam, The Netherlands) for help with setting up the (R)-[11C]verapamil PET procedure in their laboratory. Alexander Hammers from the MRC Clinical Sciences Centre (London, UK) and Marie-Claude Asselin and Rainer Hinz from the Wolfson Molecular Imaging Centre (Manchester, UK) are gratefully acknowledged for providing help in establishing the brain atlas analysis approach.
- 4.Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, Leenders KL (2008) Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2008.02.002 PubMedGoogle Scholar
- 5.Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540–548PubMedCrossRefGoogle Scholar
- 6.van Berckel BN, Lubberink M, Luurtsema G, Boellaard R, Lammertsma AA (2008) Regional variations in age dependence of P-gp mediated transport across the blood-brain barrier measured using (R)-[11C]verapamil and positron emission tomography [symposium abstract]. Alzheimers Dement 4:T95Google Scholar
- 8.Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Müller M, Baumgartner C (2007) Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil. Epilepsia 48:1774–1784PubMedCrossRefGoogle Scholar
- 9.de Klerk OL, Willemsen AT, Roosink M, Bartels AL, Harry Hendrikse N, Bosker FJ, den Boer JA (2009) Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol. doi: 10.1017/S1461145709009894 PubMedGoogle Scholar
- 11.Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Müller M (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182–190PubMedCrossRefGoogle Scholar